Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma

Gelijkaardige items

• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
  door: Jakubowiak, Andrzej J., et al.
  Gepubliceerd in: (2012)
• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
  door: Jasielec, Jagoda K., et al.
  Gepubliceerd in: (2020)
• Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
  door: Derman, Benjamin A., et al.
  Gepubliceerd in: (2021)
• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
  door: Dimopoulos, M A, et al.
  Gepubliceerd in: (2017)
• The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
  door: Wang, Tzu-Fei, et al.
  Gepubliceerd in: (2013)